🫠 This Week in Psychedelics

Welcome to Tricycle Day. We’re the newsletter that made psychedelics our whole personality. Don’t ask us about the World Cup unless you want to hear about award-winning mushroom genetics, ok? 🏆

Here’s what we got this week.

Preparation is almost as buzzy a term as integration. Almost.

But very few actually have a concrete answer for what it entails.

The Center Origin (Colorado’s very first licensed psilocybin center) has strong opinions on this topic. And they go way beyond the basics.

On June 23, they’re breaking down their approach to preparing the whole self in a free live webinar.

Their protocol touches parts of you that “set and setting” doesn't even have a vocabulary for.

Come curious and leave feeling ready.

Deeeep breaths: Breathwork is associated with greater psychedelic-like effects, emotional breakthrough, insight, and behavior change than meditation.
Hear us out: Psilocybin holds potential as a treatment for tinnitus.
Vat’s more like it: Researchers produced record levels of psilocybin and DMT in E. coli using CRISPR technology.
Golden years: UC Berkeley is investigating whether psilocybin can support healthy aging in older adults.
Sanity check: Contrary to popular belief, psychedelics don’t appear to cause psychosis. A retrospective analysis attributed the supposed link to preexisting conditions.

No funny business: Colorado’s new ibogaine law also cracks down on unlicensed psilocybin sales.
Comply or die: Meanwhile in Colorado, new rules for Natural Medicine licensees will take effect on July 1.
Bringing the receipts: Oregon Psilocybin Services published Q1 2026 data, plus a summary and recordings of its May public listening sessions.
Trial run: A New Hampshire bill that would allow healthcare providers to administer ibogaine under an FDA-approved research protocol is awaiting a final vote.
Marching orders: A House committee added language to the annual defense bill pressing the Department of Defense to track legal access pathways to psychedelic therapy for servicemembers.

Done deal: Otsuka completed its acquisition of Transcend Therapeutics, developer of methylone for PTSD.
2C or not 2C: Lophora announced Phase 1 topline results for its psychedelic phenethylamine derivative, LPH-5.
Metabolite money: DemeRx, which is launching the first U.S. clinical trial of an ibogaine-derived drug, plans to raise $25 million in series B financing this quarter.
Open books: Psychedelic Alpha released a nonprofit financing tracker that includes revenue, expenses, and executive compensation.
Got gummies? The market for unregulated gray-market psychedelics is exploding.

To infinity and beyond: Earth’s underground fungal network is so vast that, if it were unraveled into a straight line, it would span 10% of the Milky Way.
Dance it out: Taking psychedelics at raves may help heal childhood trauma.
Sacred geometry: Is the psychedelic experience just a difficult math problem?
Meme of the week: 5D view of the mushrooms reorganizing my energy body...

How you see the world says more about you than the world itself.

Might sound trite, but here’s one more reason to believe. A new study just showed that the idea holds up even when you’re tripping.

Researchers surveyed 426 psychedelic users and mapped six personality traits against the intensity of 20 sensory effects, from breathing walls to sparkly trails. And indeed, what you see is (at least partly) just you, reflected back.

Based on the research, here's how each personality trait affects the psychedelic experience.

Now before you run off and take 15 personality quizzes, we should clarify that dose, set, and setting are still far greater influences than your quirks.

But if you still feel like asking Buzzfeed which Disney princess you are based on your lunch order, by all means.

We got Pocahontas, which explains all those colors of the wind. 🫠

Can we all agree drug scheduling is due for a major update? And not just because psychedelics somehow got frozen in 1970 like the fax machine at your doctor’s office. Well, good news. Last week, Rep. Steven Cohen introduced the Controlled Substances Act Clarification in Sciences Act, which would rewrite the definition of “accepted medical use” in federal law.

Under the bill, a drug counts as having accepted medical use if a state has authorized it medically, it's widely used by practitioners there, and local regulators recognize it through rigorous evaluation. Since Schedule I is reserved for drugs with no accepted medical use, meeting that bar would knock a substance out of the most restrictive category. In other words, states could effectively force federal rescheduling by building functioning programs of their own.

Apropos of nothing, Oregon and Colorado just so happen to run regulated psilocybin programs with licensed facilitators and state oversight. And New Mexico is building one out as we type. If this framework becomes law, might these programs be what finally pry psilocybin loose from Schedule I? Would be nice. But if not, we’ve got other irons in the fire.

When SpaceX went public last Friday via the largest IPO in history, one of the biggest winners was a name many Cyclists won’t recognize. Antonio Gracias, founder of Valor Equity Partners, holds the second-largest stake in SpaceX after Elon Musk himself, a position now worth north of $68 billion.

Now, you might be wondering what this story is doing in a psychedelics newsletter. We’ll tell ya. Gracias isn’t just any rich guy. He’s also the reason MDMA still has a fighting chance of FDA approval. See, after the FDA rejected Lykos Therapeutics' PTSD application in 2024, the company’s future looked pretty grim. That’s when Gracias, with a little help from British hedge fund billionaire Chris Hohn, stepped in with a $100 million recapitalization. (What’s a hundred milly between friends?)

As the legend goes, Gracias ran into Lykos cofounder Rick Doblin at Burning Man and told him to let the company collapse and rebuild clean. Doblin apparently took the note and rebranded the rubble as Resilient Pharmaceuticals. Now, whether Gracias’s recent windfall counts as a lifeline or a Faustian bargain probably depends on how you feel about MDMA’s piggy bank drifting around Elon Musk's *ahem* orbit.

That’s all for today, Cyclists! Whenever you’re ready, here’s how we can help.

Forwarded this email? Subscribe here.

DISCLAIMER: This newsletter is for educational and informational purposes only and is not intended as a substitute for professional medical advice. The use, possession, and distribution of psychedelic drugs are illegal in most countries and may result in criminal prosecution.